廉泉穴穴位注射维生素B12和地塞米松治疗慢性咽炎的随机对照研究

注册号:

Registration number:

ITMCTR2100004844

最近更新日期:

Date of Last Refreshed on:

2021-05-14

注册时间:

Date of Registration:

2021-05-14

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

廉泉穴穴位注射维生素B12和地塞米松治疗慢性咽炎的随机对照研究

Public title:

A randomized controlled study on treating chronic pharyngitis by Lianquan acupoint injection of vitamin B12 and dexamethasone

注册题目简写:

English Acronym:

研究课题的正式科学名称:

廉泉穴穴位注射维生素B12和地塞米松治疗慢性咽炎的随机对照研究

Scientific title:

A randomized controlled study on treating chronic pharyngitis by Lianquan acupoint injection of vitamin B12 and dexamethasone

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100046348 ; ChiMCTR2100004844

申请注册联系人:

廖国庆

研究负责人:

朱力

Applicant:

Liao Guoqing

Study leader:

Zhu Li

申请注册联系人电话:

Applicant telephone:

+86 18782287430

研究负责人电话:

Study leader's telephone:

+86 28 87337925 8505

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1820884317@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1968403299@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川成都市青羊区青华路51号

研究负责人通讯地址:

四川成都市青羊区青华路51号

Applicant address:

51 Qinghua Road, Qingyang District, Chengdu, Sichuan

Study leader's address:

51 Qinghua Road, Qingyang District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都仁品耳鼻喉专科医院

Applicant's institution:

Chengdu Renpin Ear, Nose and Throat Specialist Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

20210406

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

成都仁品耳鼻喉专科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Chengdu Renpin Ear, Nose and Throat Specialist Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021/4/6 0:00:00

伦理委员会联系人:

黄丽

Contact Name of the ethic committee:

Huang Li

伦理委员会联系地址:

四川成都市青羊区青华路51号

Contact Address of the ethic committee:

51 Qinghua Road, Qingyang District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都仁品耳鼻喉专科医院

Primary sponsor:

Chengdu Renpin Ear, Nose and Throat Specialist Hospital

研究实施负责(组长)单位地址:

四川成都市青羊区青华路51号

Primary sponsor's address:

51 Qinghua Road, Qingyang District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都仁品耳鼻喉专科医院

具体地址:

青羊区青华路51号

Institution
hospital:

Chengdu Renpin Ear, Nose and Throat Specialist Hospital

Address:

51 Qinghua Road, Qingyang District

经费或物资来源:

成都仁品耳鼻喉专科医院科研专项经费

Source(s) of funding:

Special funds for research in Chengdu Renpin Ear, Nose and Throat Specialist Hospital

研究疾病:

慢性咽炎

研究疾病代码:

Target disease:

chronic pharyngitis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

评估廉泉穴穴位注射维生素B12和地塞米松在慢性咽炎患者治疗中的有效性和安全性。

Objectives of Study:

To evaluate the efficacy and safety of Lianquan acupoint injection of vitamin B12 and dexamethasone in the treatment of patients with chronic pharyngitis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合《实用耳鼻咽喉科学》中对慢性咽炎的诊断标准; 2.年龄18-65岁之间的诊断为慢性咽炎急性发作期病人; 3.入组研究前4周内未进行过针对咽炎的治疗; 4.病程 3个月-10 年; 5.签署知情同意书。

Inclusion criteria

1. Meet the diagnostic criteria for chronic pharyngitis in "Practical Otorhinolaryngology"; 2. Patients between the ages of 18-65 who are diagnosed with chronic pharyngitis during acute exacerbation; 3. No treatment for pharyngitis was performed within 4 weeks before the enrollment of the study; 4. The course of the disease was 3 months to 10 years; 5. The informed consent was signed.

排除标准:

1.罹患癌症或合并其他身体疾病及特异性咽炎(如溃疡膜性咽峡炎、病毒性咽炎、猩红热性咽炎、血液病性咽炎,如传染性单核细胞增多症、粒细胞缺乏症等)和传染性疾病引起的咽部炎症; 2.糖尿病、冠心病等严重基础性疾病者;不接受中医外治法的患者;7天内有进行过穴位注射治疗; 3.无法随访;过度焦虑、治疗期望值过高患者,孕妇和哺乳期患者。

Exclusion criteria:

1. Suffer from cancer or other physical diseases and specific pharyngitis (such as ulcerative membranous angina, viral pharyngitis, scarlet fever pharyngitis, blood disease pharyngitis, such as infectious mononucleosis, agranulocytosis, etc.) And pharyngeal inflammation caused by infectious diseases; 2. Patients with serious basic diseases such as diabetes and coronary heart disease; patients who do not receive external treatment of Chinese medicine; have had acupoint injection therapy within 7 days; 3. Unable to follow up; patients with excessive anxiety, high expectations for treatment, pregnant women and breastfeeding patients.

研究实施时间:

Study execute time:

From 2021-05-01

To      2022-05-31

征募观察对象时间:

Recruiting time:

From 2021-05-14

To      2022-06-30

干预措施:

Interventions:

组别:

干预组

样本量:

138

Group:

Intervention group

Sample size:

干预措施:

廉泉穴穴位注射维生素B12+地塞米松

干预措施代码:

Intervention:

Lianquan acupoint injection of vitamin B12 + dexamethasone

Intervention code:

组别:

对照组

样本量:

138

Group:

Control group

Sample size:

干预措施:

维生素B12+地塞米松雾化治疗

干预措施代码:

Intervention:

atomization therapy with vitamin B12 + dexamethasone

Intervention code:

样本总量 Total sample size : 276

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都仁品耳鼻喉专科医院

单位级别:

三级甲等

Institution/hospital:

Chengdu Renpin Ear, Nose and Throat Specialist Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

咽痛的视觉模拟评分

指标类型:

主要指标

Outcome:

Visual Analog Scale, VAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

症状改善时间

指标类型:

主要指标

Outcome:

Time to Symptom improvement

Type:

Primary indicator

测量时间点:

测量方法:

患者主诉症状消退时间作为记录标准

Measure time point of outcome:

Measure method:

The time of symptoms subsided was used as the recording standard

指标中文名:

临床疗效评价

指标类型:

主要指标

Outcome:

Clinical efficacy evaluation

Type:

Primary indicator

测量时间点:

测量方法:

显效:自觉全部症状消失,检查咽部黏膜充血水肿明显消失,咽后壁部淋巴滤泡萎缩、消退恢复正常,黏分泌物基本消失;有效:大部分自觉症状明显好转,检查咽部黏膜充血明显减轻,咽部淋巴滤泡等体征有所改善;无效:症状和检查无明显变化。

Measure time point of outcome:

Measure method:

Marked effect: narrate by patient, all symptoms disappeared. The congestion and edema of pharyngeal mucosa disappeared significantly. lymphoid follicles of posterior pharyngeal wall atrophied and subsided. mucous secretion disappeared. Effective: most of the self-conscious symptoms were improved. The congestion of pharyngeal muco

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

电脑生成随机数字表,研究者根据患者就诊顺序,随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Computer generated random number table, the patients were randomly assigned according to the order of them.

盲法:

评估者盲

Blinding:

Blind method for evaluators

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

拟在形成论文并公开发表后公布研究数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

We will publish research data after the paper is published.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Excel 表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel table

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统